In addition, in an intraperitoneal glucose tolerance test, Sirtris’s SIRT1 activator was shown to control glucose excursion as well as sitagliptin in this pre-clinical model of Type 2 diabetes. In contrast to DPP-4 inhibitors, which lower glucose, SIRT1 activation appears to both lower glucose and also sensitize to insulin in these models.